middle.news
Imugene’s Azer-cel Delivers 100% Response in CLL/SLL, Expands Trial Scope
11:02am on Tuesday 10th of March, 2026 AEDT
•
Healthcare
Read Story
Imugene’s Azer-cel Delivers 100% Response in CLL/SLL, Expands Trial Scope
11:02am on Tuesday 10th of March, 2026 AEDT
Key Points
100% overall response rate in CLL/SLL patients
80% overall response rate in marginal zone lymphoma
Faster enrolment in CAR T-naïve cohort than CAR T-relapsed group
Phase 1b trial expanded to include BTK inhibitor combination and mantle cell lymphoma
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMUGENE (ASX:IMU)
OPEN ARTICLE